CLAIMS

1. A pharmaceutical combination comprising:

- a compound of formula (I):



(I)

or a pharmaceutically acceptable salt thereof,

and

- at least one MAPK pathway inhibitor chosen from~~, or or a pharmaceutically acceptable salt thereof~~.

~~2. The pharmaceutical combination of claim 1, wherein the MAPK pathway inhibitor is an inhibitor of one or both of a MEK kinase and a RAF kinase.~~

~~3. The pharmaceutical combination of claim 2 , wherein the MAPK pathway inhibitor is:~~

- the compound (2a):



(2a)

or a pharmaceutically acceptable salt thereof,

~~or~~ and

- the compound (2b):



(2b)

or a pharmaceutically acceptable salt thereof.

~~4.~~2. The pharmaceutical combination of ~~any one of~~ claims 1~~ to 3~~, further comprising a pharmaceutically acceptable carrier.

~~5.~~3. The pharmaceutical combination of any one of claims 1 to 4~~2~~, comprising at least one further compound chosen from anticancer compounds.

~~6.~~4. The pharmaceutical combination of any one of claims 1 to ~~5~~3, for use as a medicament.

~~7.~~5. The use of pharmaceutical combination of any one of claims 1 to ~~6~~4, in the manufacture of a medicament for treating cancer.

~~8.~~6. Use according to claim ~~7~~5, wherein the cancer is chosen from the group consisting of: non-small cell lung cancer, breast cancer, pancreatic cancer, liver cancer, prostate cancer, bladder cancer, cervical cancer, thyroid cancer, colorectal cancer, liver cancer, muscle cancer, hematological malignancies, melanoma, endometrial cancer and pancreatic cancer.

~~9.~~7. Use according to claim ~~7~~5, wherein the cancer is chosen from the group consisting of: colorectal cancer, endometrial cancer, hematological malignancies, thyroid cancer, breast cancer, melanoma, pancreatic cancer and prostate cancer.

~~10.~~8. The use according to claim ~~7~~5, wherein administration of the compound of formula (I) is to be followed by the administration of the MAPK pathway inhibitor.

~~11.~~9. The use according to claim ~~7~~5, wherein administration of the MAPK pathway inhibitor is to be followed by the administration of the compound of formula (I).

~~12.~~10. The use according to claim ~~7~~5, wherein administration of the compound of formula (I) is to be followed by the administration of the compound (2a).

~~13.~~11. The use according to claim ~~7~~5, wherein administration of the compound of formula (I) is to be followed by the administration of the compound (2b).

~~14.~~12. The use according to claim ~~7~~5, wherein administration of the compound (2a) is to be followed by the administration of the compound of formula (I).

~~15.~~13. The use according to claim ~~7~~5, wherein administration of the compound (2b) is to be followed by the administration of the compound of formula (I).

~~16. The use according to claim 7, wherein the compound of formula (I) and the MAPK pathway inhibitor are in amounts that produce a synergistic effect in reducing tumor volume.~~

~~17. The use according to claim 7, wherein the compound of formula (I) and the MAPK pathway inhibitor are in amounts that produce a combined effect of tumor stasis.~~

~~18. A product comprising:~~

~~a compound of formula (I):~~



~~(I)~~

~~or a pharmaceutically acceptable salt thereof,~~

~~and~~

~~at least one MAPK pathway inhibitor, or a pharmaceutically acceptable salt thereof,~~

~~as a combined preparation for simultaneous, separate or sequential use in anticancer therapy.~~

~~19.~~14. A kit comprising:

- at least one compound of formula (I):